Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Smartsheet And Asana’s Contrasting Q4 Forecast Amid Macro Headwinds Surprises Analyst

KeyBanc analyst Jason Celino reiterated an Overweight rating on Smartsheet Inc (NYSE:SMAR) with a $46 price target. Celino maintained a Sectorweight rating…
byAnusuya Lahiri
December 2, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0
  • KeyBanc analyst Jason Celino reiterated an Overweight rating on Smartsheet Inc (NYSE:SMAR) with a $46 price target.
  • Celino maintained a Sectorweight rating on Asana, Inc (NYSE:ASAN). The analyst sees fair value at $16 based on 5x FY24E EV/revenue.
  • Work management peers Smartsheet and Asana reported starkly different Q3 results. 
  • SMAR reported a solid Q3 beat and better Q4 guidance, while ASAN posted mixed results and lowered Q4 guidance. 
  • Smartsheet reported third-quarter revenue growth of 38% year-on-year to $199.6 million, beating the consensus of $194.3 million.
  • Non-GAAP EPS loss of $(0.01) beat the consensus loss of $(0.15).
  • Smartsheet sees Q4 revenue of $205 million – $207 million (vs. consensus $204.4 million), non-GAAP EPS loss of $(0.02) – $(0.00) (vs. consensus loss $(0.09)).
  • Asana’s Q3 revenue increased 41% year-over-year to $141.4 million, beating the consensus of $139.37 million. 
  • Non-GAAP EPS loss of $(0.26) beat the consensus loss of $(0.32).
  • Asana expects Q4 revenue to be $144 million – $146 million versus average estimates of $151.06 million. The company anticipates a non-GAAP EPS loss of $(0.27) – $(0.28) versus a consensus loss of $(0.29).
  • Though both companies mentioned worsening macro, SMAR looks to be executing well, with ASAN facing incremental challenges given the company’s exposure to tech and more limited cross-sell go-to-market. 
  • Price Action: SMAR shares traded higher by 15.26% at $37.47 on the last check Friday.
 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Innoviva Stock Trading Halted Today; FDA Advisory Committee To Review Sulbactam-Durlobactam For The Treatment Of Hospital-Acquired And Ventilator-Associated Bacterial Pneumonia Caused By Susceptible Strains Of Acinetobacter

By Happy Mohamed
April 17, 9:09 AM
FDA Advisory Committee to review sulbactam-durlobactam for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter Innoviva, Inc. (NASDAQ:INVA)

INVA

Read More

Snap-on’s Q4 Earnings Beat Can’t Hide Revenue Miss, Will Growth Stall?

By Lekha Gupta
February 8, 2:16 PM
Snap-on posts Q4 FY23 results with a 3.5% sales increase to $1.197 billion, driven by organic gains and favorable currency translation. Despite missing consensus, the company's gross profit rises to $577.6 million, with operating earnings climbing to $325.8 million, surpassing EPS expectations at $4.75. CEO Nick Pinchuk notes positive momentum in critical industries and strategic acquisition benefits. Snap-on outlines FY24 outlook, expecting capital expenditures of $100-110 million.

SNA